Drug Profile


Alternative Names: Acuatim; Nadixa; OPC-7251

Latest Information Update: 22 Apr 2009

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Ferrer; Otsuka Pharmaceutical
  • Class Antibacterials; Fluoroquinolones; Quinolizines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 24 May 2004 Launched for Acne vulgaris in Germany (Topical)
  • 25 Aug 2003 Withdrawn for Acne vulgaris in Latin America (Topical)
  • 25 Aug 2003 Discontinued - Phase-II clinical trials in Acne vulgaris in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top